국가: 영국
언어: 영어
출처: MHRA (Medicines & Healthcare Products Regulatory Agency)
Insulin soluble human
Sanofi
A10AB01
Insulin soluble human
100unit/1ml
Solution for injection
Intravenous; Subcutaneous
No Controlled Drug Status
VMP not recommended to prescribe - patient training required
BNF: 06010101; GTIN: 5013841202125
541561 전체 문서 읽기541561 SAP-NR. (DMC): 541561 SCHRIFTGRÖSSE: 9 PUNKT DRUCKFARBEN: PANTONE REFLEX BLUE FORMAT: 420 X 296 MM ERSTELLT AM: 18. APRIL 2018 / VERSION: 1 / MAC 541561 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. THE INSTRUCTIONS FOR USING THE INSULIN PEN ARE PROVIDED WITH YOUR INSULIN PEN. REFER TO THEM BEFORE USING YOUR MEDICINE. – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doctor, pharmacist or nurse. – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. – If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Insuman Rapid is and what it is used for 2. What you need to know before you use Insuman Rapid 3. How to use Insuman Rapid 4. Possible side effects 5. How to store Insuman Rapid 6. Contents of the pack and other information 1. WHAT INSUMAN RAPID IS AND WHAT IT IS USED FOR Insuman Rapid contains the active substance insulin human which is made by a biotechnology process and is identical with the body's own insulin. Insuman Rapid is an insulin solution with a rapid onset and short duration of action. Insuman Rapid is used to reduce high blood sugar in patients with diabetes mellitus who need treatment with insulin. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE INSUMAN RAPID DO NOT USE INSUMAN RAPID If you are allergic to insulin or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Insuman Rapid in cartridges is only suitable for injecting just under the skin using a reusable pen (see also section 3). Speak to your doctor if you need to inject your insulin by another method. Talk to you
OBJECT 1 INSUMAN RAPID 100 IU/ML SOLUTION FOR INJECTION IN A CARTRIDGE Summary of Product Characteristics Updated 13-Apr-2018 | SANOFI 1. Name of the medicinal product Insuman Rapid 100 IU/ml solution for injection in a cartridge 2. Qualitative and quantitative composition Insuman Rapid 100 IU/ml in a cartridge Each ml contains 100 IU insulin human (equivalent to 3.5 mg). Each cartridge contains 3 ml of solution for injection, equivalent to 300 IU insulin. One IU (International Unit) corresponds to 0.035 mg of anhydrous human insulin * . Insuman Rapid is a neutral insulin solution (regular insulin). * Human insulin is produced by recombinant DNA technology in _Escherichia coli_. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Solution for injection. Clear, colourless solution. 4. Clinical particulars 4.1 Therapeutic indications Diabetes mellitus where treatment with insulin is required. 4.2 Posology and method of administration Posology The desired blood glucose levels, the insulin preparations to be used and the insulin dose regimen (doses and timings) must be determined individually and adjusted to suit the patient's diet, physical activity and life-style. _Daily doses and timing of administration _ There are no fixed rules for insulin dose regimen. However, the average insulin requirement is often 0.5 to 1.0 IU per kg body weight per day. The basal metabolic requirement is 40% to 60% of the total daily requirement. Insuman Rapid is injected subcutaneously 15 to 20 minutes before a meal. _Secondary dose adjustment _ Improved metabolic control may result in increased insulin sensitivity, leading to a reduced insulin requirement. Dose adjustment may also be required, for example, if - the patient's weight changes, - the patient's life-style changes, - other circumstances arise that may promote an increased susceptibility to hypo- or hyperglycaemia (see section 4.4). _Special populations _ _Elderly population(_ _65 years old)_ ≧ In the elderly, progressive deterioration of renal function 전체 문서 읽기